HCPCS Code J2354: Octreotide non-depot injection billing guide

Key takeaways

HCPCS Code J2354 describes injection of octreotide acetate in non-depot form, 25 mcg per unit, via subcutaneous or intravenous route.

Each billing unit equals exactly 25 mcg. Divide the prescribed dose by 25 to calculate units, and verify the total against the prescribing order before submitting.

Confusing J2354 (non-depot) with J2353 (depot/LAR form) is the most common denial trigger, since the two formulations have different dosing intervals and reimbursement rates.

Practice management software like Pabau supports accurate J2354 charge capture through structured treatment notes documenting dose and diagnosis.

HCPCS Code J2354 is the billing code for the non-depot form of octreotide acetate, administered subcutaneously or intravenously at 25 mcg per unit. It is a Level II HCPCS J-code maintained by the Centers for Medicare and Medicaid Services (CMS). CMS uses it to reimburse Medicare Part B drugs administered in physician offices and outpatient settings.

Octreotide has two billing codes for two different formulations. J2354 covers the non-depot, immediate-release form used in this guide, and J2353 covers the long-acting depot form. The near-identical drug names make the two easy to confuse on a claim.

This reference covers code details, formulation differences, ICD-10 pairing, Medicare reimbursement, unit calculation, place-of-service rules, the NDC crosswalk, and common billing errors.

HCPCS Code J2354: Code details and description

J2354 is the standard code for physician-administered octreotide in non-depot form. Its precise descriptor matters because Medicare and commercial payers use the exact language to evaluate medical necessity and formulation appropriateness.

J2354 is part of the HCPCS Level II codes maintained by CMS, which cover drugs, biologicals, and other items not captured by CPT codes. The descriptor must match exactly on the CMS-1500 or 837P electronic claim. Accurate treatment notes at the point of care help prevent mismatches before submission.

Non-depot vs depot form: Understanding the J2354 vs J2353 distinction

The single most common billing error with octreotide is submitting the wrong formulation code. J2353 and J2354 are not interchangeable. They describe pharmacologically distinct products with different dosing intervals, routes, and reimbursement structures.

Non-depot octreotide (J2354) is used for acute symptom management, dose titration initiation, and patients who cannot tolerate intramuscular depot injections. The depot form (J2353) is typically used for maintenance therapy once a stable dose has been established. Submitting J2353 when the patient received the non-depot formulation constitutes a coding error that payers flag during post-payment audits.

Clinical indications and supporting ICD-10 codes for J2354

Medical necessity is the gatekeeper for J2354 reimbursement. Every claim must be paired with a supported ICD-10 diagnosis code confirming the clinical indication. The FDA has approved octreotide acetate for three primary conditions, and Medicare Local Coverage Determinations (LCDs) from Medicare Administrative Contractors (MACs) specify which diagnoses qualify.

FDA-approved indications

• Acromegaly: reduction of growth hormone and IGF-1 levels in patients with inadequate response to surgery, radiation, or bromocriptine
• Carcinoid syndrome: symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
• VIPomas: treatment of profuse watery diarrhea caused by vasoactive intestinal peptide-secreting tumors

Supporting ICD-10 diagnosis codes

Off-label use of octreotide exists for conditions such as refractory GI bleeding, portal hypertension, and certain types of chronic diarrhea. Some of these show up in functional medicine practices working alongside gastroenterology. Billing J2354 for off-label indications without specific LCD coverage creates significant audit risk. Always confirm the patient’s diagnosis maps to an LCD-supported ICD-10 code before submitting.

Practices managing ICD-10 pairings across multiple drug therapies benefit from a structured approach to clinical documentation at the point of care. That reduces the risk of mismatched diagnosis codes at claim submission.

Medicare reimbursement for HCPCS Code J2354

Medicare Part B reimburses physician-administered drugs under J-codes using the Average Sales Price (ASP) methodology, established under Section 1847A of the Social Security Act. For J2354, the statutory payment rate is ASP plus 6% of ASP, calculated per 25 mcg billing unit.

A 2% Medicare sequestration cut has applied to Part B drug payments since 2013, so the effective add-on works out closer to ASP plus 4.3%. Practices should verify the current effective rate before relying on it.

ASP pricing methodology and quarterly updates

CMS publishes updated ASP drug pricing files quarterly, typically four times per year. The ASP reflects the weighted average sales price manufacturers report to CMS, net of rebates and discounts. Because ASP fluctuates each quarter, J2354 reimbursement rates change accordingly.

The correct approach is to reference the CMS Physician Fee Schedule tool for the current quarter’s payment limit for J2354. Stating a fixed dollar amount in billing documentation creates compliance risk when rates update. Practices should build a quarterly pricing review into their revenue cycle calendar.

Reimbursement by setting

The buy-and-bill model applies primarily in physician office settings. Under this model, the practice purchases the drug directly, administers it, and bills Medicare for reimbursement.

The practice assumes the inventory and carrying cost risk. The ASP plus 6% markup is intended to offset that cost. Practices billing under this model need robust inventory tracking and documentation to withstand a Medicare audit.

Billing guidelines and unit calculation for J2354

Incorrect unit calculation is the second most common denial trigger for J2354 claims, after wrong formulation code. Each billing unit equals exactly 25 mcg of octreotide non-depot form. The calculation is straightforward but must be precise.

Unit calculation formula

Units to bill = Prescribed dose in mcg divided by 25

For example: a physician orders 100 mcg of octreotide subcutaneously. Divide 100 by 25 to get 4 units. Submit J2354 with 4 units on the claim. A common dose of 50 mcg equals 2 units, and 150 mcg equals 6 units. Always round based on actual administered dose, not prescribed dose, if a partial vial is wasted.

Billing workflow steps

1. Confirm the administered formulation is non-depot octreotide (not Sandostatin LAR Depot)
2. Record the actual dose administered in mcg in the clinical note
3. Calculate units: divide administered dose by 25
4. Verify the patient’s ICD-10 diagnosis code is LCD-supported for octreotide
5. Select place of service code matching the administration site
6. Include the NDC code on the claim if required by the payer (Medicaid and many commercial plans require NDC reporting)
7. Submit J2354 with the calculated unit count on the CMS-1500 or 837P claim

Practices that handle multiple injectable drugs benefit from a standardized documentation workflow. Pabau’s prescription management software sends the order to the pharmacy electronically. That keeps a consistent record of what was prescribed, next to the clinical note billers use for unit calculation.

NDC codes and drug crosswalk for J2354

NDC (National Drug Code) reporting is required for J2354 claims submitted to Medicaid. Many commercial payers also require NDC codes. The NDC must correspond to the specific octreotide product actually dispensed, not a generic placeholder. Below are common NDC mappings for octreotide non-depot products billed under J2354.

Verify current NDC numbers against the NLM HCPCS API or your pharmacy’s current stock labeling. NDC numbers can change when manufacturers update packaging or concentrations. Always report the NDC from the specific lot administered, not a memorized number.

Medicaid programs have strict NDC reporting requirements. Billing without a valid NDC on a Medicaid claim is a common cause of avoidable denials.

Related HCPCS codes and J2354 crosswalk

Understanding the code landscape around J2354 helps billers avoid misuse and supports accurate crosswalking when switching formulations or coding neuroendocrine tumor therapies. Billers managing a broad HCPCS code set also encounter items like B4197, E0190, and C1779. These follow the same Level II coding structure as J2354.

When a patient transitions from non-depot to depot octreotide, update the HCPCS code to J2353. Recalculate units using the depot billing unit of 1 mg per unit. Both codes should never appear on the same claim for the same date of service unless two separate administrations occurred under separate clinical orders.

Prior authorization requirements

Medicare does not universally require prior authorization for J2354, but requirements vary significantly by Medicare Advantage plan, MAC jurisdiction, and commercial payer. The AAPC HCPCS code reference provides payer-specific policy notes, though practices should always verify directly with the payer before administration.

• Traditional Medicare (Parts A and B): Prior authorization typically not required for FDA-approved indications with a supported ICD-10 code; however, MAC-specific LCDs may impose coverage criteria that function as de facto authorization requirements
• Medicare Advantage plans: Many plans require prior authorization; requirements vary by plan and formulary year
• Commercial payers: Most require prior authorization for specialty drugs including octreotide; step therapy requirements (demonstrating failure of other agents first) are common
• Medicaid: State-specific; prior authorization is common, particularly for non-oncology indications

Documentation requirements for prior authorization typically include the confirmed diagnosis with ICD-10 code and evidence of medical necessity, such as labs, imaging, or specialist notes. Payers also expect prescribing physician credentials, and for acromegaly, growth hormone and IGF-1 level data.

Storing this documentation in Pabau’s treatment notes and patient records keeps it organized and easy to retrieve when a payer requests a prior authorization file.

Common billing errors and how to avoid them

Octreotide claims have a higher-than-average denial rate because the code pair (J2353/J2354), unit calculation, and LCD compliance all represent independent failure points. Addressing these proactively reduces rework and protects against post-payment audit recovery.

Practices with an active HIPAA compliance program tend to catch these errors at the charge capture stage rather than at claims adjudication. Structured medical office compliance workflows make that possible, and significantly reduce the cost of rework. Regular internal audits of octreotide claims, spot-checking unit counts and ICD-10 pairings, are an effective safeguard against systematic billing errors.

How Pabau supports accurate documentation for J2354 claims

Most J2354 denials start before the claim is even coded. A dose scribbled on paper, a diagnosis missing from the note, or an inconsistent formulation name across visits all create the same downstream problem. Getting the underlying documentation right is what makes accurate billing possible.

Endocrinology practices, oncology clinics, and metabolic health practices all depend on precise documentation to get an octreotide claim paid correctly the first time. Pabau gives them a structured treatment note for every administration. It captures the formulation, dose, and diagnosis code in one place, rather than scattered across paper charts or a separate spreadsheet.

That consistency is what a biller needs to translate a visit into an accurate claim, whichever formulation code applies. Practices spend less time chasing missing details after the fact and more time on patient care.

Keep J2354 documentation accurate and consistent

Pabau's treatment notes capture the formulation, dose, and diagnosis for every octreotide administration in one patient record. Your billing team gets everything it needs to code the claim correctly.

Book a demo

Conclusion

Get the formulation code right, calculate units from the administered dose, and pair the claim with an LCD-supported diagnosis, and most J2354 denials never happen. Skip any one of the three and the claim comes back, regardless of how quickly the rest of the paperwork moves.

The fix is rarely more coding staff. It’s a documentation habit that captures dose, formulation, and diagnosis at the point of care, before a biller has to reconstruct it after the fact.

Book a demo to see how Pabau’s treatment notes keep that detail consistent for every octreotide administration.

Continue your research

Billing another physician-administered oncology drug? J9312 covers rituximab, sharing the same ASP-based Medicare reimbursement approach as J2354.

Coding a home injectable therapy that doesn’t fit a named code? S9542 is the not-otherwise-classified per diem code for home injectable drug administration.

Need a quick endocrinology knowledge check for your team? The endocrinology quiz template covers hormones, feedback mechanisms, and thyroid and adrenal disorders.

Frequently asked questions